HER2-positive metastatic breast cancer

A changing scenario

G. Mustacchi, L. Biganzoli, P. Pronzato, F. Montemurro, M. Dambrosio, M. Minelli, L. Molteni, L. Scaltriti

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Adjuvant trastuzumab (AT) dramatically improved HER2-positive breast cancer prognosis. Relapsed disease after AT has different patterns and information is available from observational studies. In this Review Chemotherapy regimens combined to anti-HER2 blockade are discussed, focusing in particular the role of anthracyclines, taxanes and capecitabine. The use of trastuzumab beyond progression and the role of other anti-HER2 agents like lapatinib, pertuzumab and T-DM1 are explored, as also dual blockade and in trastuzumab resistant Patients. Metastatic "de novo" HER2 Luminal (co-expression of HER2 and hormone receptors) Patients are eligible for anastrozole and trastuzumab but if pretreated with trastuzumab they are also eligible for lapatinib and letrozole. In any case endocrine treatment plays a complementary role to chemotherapy which remains pivotal. The last topic explored is treatment options for patients with brain metastases where both trastuzumab given concurrent with radiotherapy or lapatinib and capecitabine appear as potentially active.

Original languageEnglish
Pages (from-to)78-87
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume95
Issue number1
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Breast Neoplasms
letrozole
Drug Therapy
Taxoids
Anthracyclines
Trastuzumab
Observational Studies
Radiotherapy
Hormones
Neoplasm Metastasis
Brain
Therapeutics
lapatinib
Capecitabine

Keywords

  • Breast cancer
  • HER2
  • Metastatic disease
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

HER2-positive metastatic breast cancer : A changing scenario. / Mustacchi, G.; Biganzoli, L.; Pronzato, P.; Montemurro, F.; Dambrosio, M.; Minelli, M.; Molteni, L.; Scaltriti, L.

In: Critical Reviews in Oncology/Hematology, Vol. 95, No. 1, 01.07.2015, p. 78-87.

Research output: Contribution to journalArticle

Mustacchi, G, Biganzoli, L, Pronzato, P, Montemurro, F, Dambrosio, M, Minelli, M, Molteni, L & Scaltriti, L 2015, 'HER2-positive metastatic breast cancer: A changing scenario', Critical Reviews in Oncology/Hematology, vol. 95, no. 1, pp. 78-87. https://doi.org/10.1016/j.critrevonc.2015.02.002
Mustacchi, G. ; Biganzoli, L. ; Pronzato, P. ; Montemurro, F. ; Dambrosio, M. ; Minelli, M. ; Molteni, L. ; Scaltriti, L. / HER2-positive metastatic breast cancer : A changing scenario. In: Critical Reviews in Oncology/Hematology. 2015 ; Vol. 95, No. 1. pp. 78-87.
@article{6e36076d2841477fb8c936f5be5d84b7,
title = "HER2-positive metastatic breast cancer: A changing scenario",
abstract = "Adjuvant trastuzumab (AT) dramatically improved HER2-positive breast cancer prognosis. Relapsed disease after AT has different patterns and information is available from observational studies. In this Review Chemotherapy regimens combined to anti-HER2 blockade are discussed, focusing in particular the role of anthracyclines, taxanes and capecitabine. The use of trastuzumab beyond progression and the role of other anti-HER2 agents like lapatinib, pertuzumab and T-DM1 are explored, as also dual blockade and in trastuzumab resistant Patients. Metastatic {"}de novo{"} HER2 Luminal (co-expression of HER2 and hormone receptors) Patients are eligible for anastrozole and trastuzumab but if pretreated with trastuzumab they are also eligible for lapatinib and letrozole. In any case endocrine treatment plays a complementary role to chemotherapy which remains pivotal. The last topic explored is treatment options for patients with brain metastases where both trastuzumab given concurrent with radiotherapy or lapatinib and capecitabine appear as potentially active.",
keywords = "Breast cancer, HER2, Metastatic disease, Trastuzumab",
author = "G. Mustacchi and L. Biganzoli and P. Pronzato and F. Montemurro and M. Dambrosio and M. Minelli and L. Molteni and L. Scaltriti",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.critrevonc.2015.02.002",
language = "English",
volume = "95",
pages = "78--87",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - HER2-positive metastatic breast cancer

T2 - A changing scenario

AU - Mustacchi, G.

AU - Biganzoli, L.

AU - Pronzato, P.

AU - Montemurro, F.

AU - Dambrosio, M.

AU - Minelli, M.

AU - Molteni, L.

AU - Scaltriti, L.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Adjuvant trastuzumab (AT) dramatically improved HER2-positive breast cancer prognosis. Relapsed disease after AT has different patterns and information is available from observational studies. In this Review Chemotherapy regimens combined to anti-HER2 blockade are discussed, focusing in particular the role of anthracyclines, taxanes and capecitabine. The use of trastuzumab beyond progression and the role of other anti-HER2 agents like lapatinib, pertuzumab and T-DM1 are explored, as also dual blockade and in trastuzumab resistant Patients. Metastatic "de novo" HER2 Luminal (co-expression of HER2 and hormone receptors) Patients are eligible for anastrozole and trastuzumab but if pretreated with trastuzumab they are also eligible for lapatinib and letrozole. In any case endocrine treatment plays a complementary role to chemotherapy which remains pivotal. The last topic explored is treatment options for patients with brain metastases where both trastuzumab given concurrent with radiotherapy or lapatinib and capecitabine appear as potentially active.

AB - Adjuvant trastuzumab (AT) dramatically improved HER2-positive breast cancer prognosis. Relapsed disease after AT has different patterns and information is available from observational studies. In this Review Chemotherapy regimens combined to anti-HER2 blockade are discussed, focusing in particular the role of anthracyclines, taxanes and capecitabine. The use of trastuzumab beyond progression and the role of other anti-HER2 agents like lapatinib, pertuzumab and T-DM1 are explored, as also dual blockade and in trastuzumab resistant Patients. Metastatic "de novo" HER2 Luminal (co-expression of HER2 and hormone receptors) Patients are eligible for anastrozole and trastuzumab but if pretreated with trastuzumab they are also eligible for lapatinib and letrozole. In any case endocrine treatment plays a complementary role to chemotherapy which remains pivotal. The last topic explored is treatment options for patients with brain metastases where both trastuzumab given concurrent with radiotherapy or lapatinib and capecitabine appear as potentially active.

KW - Breast cancer

KW - HER2

KW - Metastatic disease

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84930822761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930822761&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.02.002

DO - 10.1016/j.critrevonc.2015.02.002

M3 - Article

VL - 95

SP - 78

EP - 87

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -